Kineta and researchers from the University of Groningen, Netherlands, announced new data from a study that showed dalazatide (formerly ShK-186) is effective in immunomodulating the cells causing inflammation and damage of small blood vessels in various organs in samples from patients with Granulomatosis with Polyangiitis (GPA). The data were presented at the 17th International ANCA and Vasculitis Workshop in London by Kineta collaborators Lucas L. Lintermans and Dr. Wayel H. Abdulahad.
ANCA-associated vasculitis illnesses such as GPA are rare autoimmune diseases but can be severe, affecting multiple organ systems and leading to kidney failure and lung hemorrhage. The collaboration between Kineta and the University of Groningen was based on earlier published research by Dr. Abdulahad showing that during flares of disease, GPA patients had elevated numbers of effector memory T cells in their urine.
“A key question was whether these effector memory T cells expressed high levels of Kv1.3 and could be functionally blocked by dalazatide,” stated Dr. Ernesto J. Muñoz, Associate Director of Translational Immunology at Kineta.